HOME >> BIOLOGY >> NEWS
K-State researcher working to improve alternatives to equine antibiotics

Davis said she also hopes to find which motifs are the most stimulating to equine immune cells as well as how the immune response is initiated. Such research would continue to drive the development of more effective commercial immune stimulants.

"I think we could improve on something that works well," Davis said about the commercial stimulants. "The ultimate goal would be to reduce antibiotic usage for infectious diseases. People do commonly use the commercial products, so I think there would be some interest to have something that was better."

Davis is completing her Ph.D. under the direction of Dr. Frank Blecha.

"The antimicrobial peptide cloning/sequencing work has been part of my graduate work; the immunomodulation with CpG DNA studies are my current focus," Davis said.


'"/>

Contact: Elizabeth Davis, DVM
edavis@vet.k-state.edu
785-532-5700
Kansas State University
22-Jul-2004


Page: 1 2

Related biology news :

1. K-State, other universities to study how climate affects plant evolution
2. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
3. K-State professor combines love of teaching, research to examine eye development
4. K-State business researchers to help with major study on food supply veterinary medicine
5. K-State researchers share $1 million grant to study insect pests
6. K-State soil carbon sequestration research playing role in climate change efforts
7. K-State uses geographic tools to track plant pathogens
8. K-State professor to give paper on potential impact of ag bioterrorism
9. K-State scientists beetle chosen for national genome sequencing project
10. New science at K-State attracts $4.2 million from National Science Foundation
11. K-State professor examines connections between food, culture and psychology in new book

Post Your Comments:
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: